Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection.

[1]  T. Hickish,et al.  A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  T. Gruenberger,et al.  Liver Resection Remains a Safe Procedure After Neoadjuvant Chemotherapy Including Bevacizumab: A Case-Controlled Study , 2010, Annals of surgery.

[3]  L. Ellis,et al.  Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  L. Ellis,et al.  Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  W. Scheithauer,et al.  Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Thomas Gruenberger,et al.  Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  F. Lévi,et al.  Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Thomas Gruenberger,et al.  Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial , 2008, The Lancet.

[9]  P. Tekkis,et al.  Evaluation of Long-term Survival After Hepatic Resection for Metastatic Colorectal Cancer: A Multifactorial Model of 929 Patients , 2008, Annals of surgery.

[10]  H. Hurwitz,et al.  Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. , 2008, Journal of the American College of Surgeons.

[11]  A. Carrato,et al.  Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. , 2007, European journal of cancer.

[12]  S. Curley,et al.  Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy. , 2007, Journal of the American College of Surgeons.

[13]  P. Catalano,et al.  Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Gonen,et al.  Lack of Evidence for Increased Operative Morbidity After Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study , 2007, Annals of Surgical Oncology.

[15]  J. Cameron,et al.  Assessment of Complications After Pancreatic Surgery: A Novel Grading System Applied to 633 Patients Undergoing Pancreaticoduodenectomy , 2006, Annals of surgery.

[16]  M. Ychou,et al.  Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. , 2006, European journal of cancer.

[17]  L. Canedo,et al.  Strategies to treat primary unresectable colorectal liver metastases. , 2005, Seminars in oncology.

[18]  Bernard Paule,et al.  Rescue Surgery for Unresectable Colorectal Liver Metastases Downstaged by Chemotherapy: A Model to Predict Long-term Survival , 2004, Annals of surgery.

[19]  N. Demartines,et al.  Classification of Surgical Complications: A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey , 2004, Annals of Surgery.

[20]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[21]  J. Pignon,et al.  Results of R0 Resection for Colorectal Liver Metastases Associated With Extrahepatic Disease , 2004, Annals of Surgical Oncology.

[22]  R. Adam,et al.  Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  J. Faivre,et al.  [Epidemiology of colorectal cancer liver metastases]. , 2003, Bulletin de l'Academie nationale de medecine.

[24]  Michael A. Choti,et al.  Trends in Long-Term Survival Following Liver Resection for Hepatic Colorectal Metastases , 2002, Annals of surgery.

[25]  J. Geoghegan,et al.  Treatment of colorectal liver metastases , 1999, The British journal of surgery.

[26]  W. Enker,et al.  Liver resection for colorectal metastases. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.